Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8WBAH)

Drug Name
DEXMETHYLPHENIDATE HYDROCHLORIDE Drug Info
Synonyms
Dexmethylphenidate hydrochloride; Focalin; D-threo-Methylphenidate hydrochloride; Dexmethylphenidate HCl; Focalin XR; UNII-1678OK0E08; Dexmethylphenidate hydrochloride [USAN]; 19262-68-1; 1678OK0E08; 23655-65-4; CHEMBL904; Methyl (2R)-phenyl((2R)-piperidin-2-yl)acetate hydrochloride; dl-threo-Methylphenidate Hydrochloride; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (R-(R*,R*))-; 2-Piperidineacetic acid, alpha-phenyl-, methyl ester, hydrochloride, (alphaR,2R)-; Dexmethylphenidate; NWP06
Indication
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Approved [1]
Cross-matching ID
PubChem CID
154100
CAS Number
CAS 19262-68-1
TTD Drug ID
DM8WBAH
VARIDT Drug ID
DR00844

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Dopamine transporter (DAT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [3]
Dasotraline DMLDQFV Attention deficit hyperactivity disorder 6A05.Z Approved [4]
Methylphenidate DM7SJD6 Attention deficit hyperactivity disorder 6A05.Z Approved [5]
Modafinil DMYILBE Malignant glioma 2A00.0 Approved [6]
Phenmetrazine DMXYTN9 Obesity 5B81 Approved [7]
Ioflupane i-123 DMNARJT Parkinson disease 8A00.0 Approved [1]
Altropane DMO9WDS Attention deficit hyperactivity disorder 6A05.Z Approved [8]
Amitifadine DMS1X67 Obesity 5B81 Phase 3 [9]
NAV5001 DMRSI1M Dementia 6D80-6D86 Phase 3 [8]
MIN-117 DMSLIW6 Major depressive disorder 6A70.3 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine transporter (DAT) TTVBI8W SC6A3_HUMAN Inhibitor [2]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
3 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
4 Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
5 Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
8 Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)